Joe Yujiao Chang, MD,PhD
Affiliations: |
Area:
Radiation Oncology; Lung CancerWebsite:
https://faculty.mdanderson.org/profiles/joe_chang.htmlGoogle:
"Joe Chang"Parents
Sign in to add mentor| Mien-Chie Hung | grad student | 1997 | The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (E-Tree) | |
| ("Targeting of HER-2/neu with E1A gene therapy.") | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Corrigan KL, Xu T, Sasaki Y, et al. (2024) Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 110121 |
| Wisdom AJ, Barker CA, Chang JY, et al. (2024) The next chapter in immunotherapy and radiation combination therapy - cancer-specific perspectives. International Journal of Radiation Oncology, Biology, Physics |
| Tate MK, Hernandez M, Chang JY, et al. (2024) Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Research. 44: 133-137 |
| Zhu XR, Li Y, Yang M, et al. (2023) Stereotactic body proton therapy for early stage non-small cell lung cancer - Technical challenges and solutions: The MD Anderson experience. Journal of Radiosurgery and Sbrt. 9: 75-82 |
| Weidhaas JB, Hu C, Komaki R, et al. (2023) The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC. Cancer Research Communications |
| Chang JY, Lin SH, Dong W, et al. (2023) Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet (London, England) |
| Ettinger DS, Wood DE, Aisner DL, et al. (2023) NCCN GuidelinesĀ® Insights: Non-Small Cell Lung Cancer, Version 2.2023. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 340-350 |
| Wu Y, Verma V, Gay CM, et al. (2023) Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Cancer |
| De B, Farooqi AS, Mitchell KG, et al. (2023) Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals Mutations to Be Associated With Longer Overall Survival. Jco Precision Oncology. 7: e2200540 |
| Zhu Z, Ni J, Cai X, et al. (2022) International consensus on radiotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research. 11: 1763-1795 |